Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas VP-Business Development Masaki Doi: An Interview With "The Pink Sheet" DAILY (Part 2 0f 2)

This article was originally published in PharmAsia News

Executive Summary

"The Pink Sheet" DAILY visited recently with Astellas Pharma VP-Business Development Masaki Doi at the company's headquarters in Tokyo to talk about the Japanese pharma's global licensing strategy and the changing paradigm of Japanese deal flow. This is the second of a two-part interview. (Part 1 was printed yesterday in PharmAsia News).

You may also be interested in...



Pfizer, Astellas Execs Talk Deals At BIO Asia

TOKYO - Although the economic slump may seem like an opportune time for more mergers and acquisitions with big pharmas taking over biotechs, there are challenges to such an approach, pharma executives told attendees of the annual BIO Asia partnering conference Jan. 19

Pfizer, Astellas Execs Talk Deals At BIO Asia

TOKYO - Although the economic slump may seem like an opportune time for more mergers and acquisitions with big pharmas taking over biotechs, there are challenges to such an approach, pharma executives told attendees of the annual BIO Asia partnering conference Jan. 19

Mitsubishi, Tanabe Merge To Accelerate International Business Development

Consolidated company will be the fifth largest Japanese drug maker.

Related Content

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel